Breast Cancer Early Stage Breast Cancer (Stage 1-3)BC-CHATNCT06943911
Reflects the Intervention (AI Chatbot)
A study testing AI Chatbot for Breast Cancer Patient Education and Empowerment in people with Breast Cancer Early Stage Breast Cancer (Stage 1-3), run by Mostafa Shaban at 1 site in Egypt.
Trial summary
The goal of this clinical trial is to investigate the impact of an AI-powered chatbot intervention on improving knowledge, attitudes, and empowerment in breast cancer patients. The study focuses on female breast cancer patients, aged 18 years or older, who are receiving treatment at Kafr El-Sheikh University Hospital… Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- What is being tested?
- AI Chatbot for Breast Cancer Patient Education and Empowerment
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 122 participants
- Where
- 1 siteEgypt
- Study dates
- 20 Apr 2025to 15 Jul 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Female participants diagnosed with breast cancer, regardless of cancer stage.
- Age 18 years or older.
- Ability to read and communicate in Arabic to interact with the AI chatbot.
- Willingness to participate in the study and to engage with the AI chatbot for the duration of the intervention.
- Ability to provide informed consent.
Who cannot join
- Participants with cognitive impairments or serious mental health conditions that may hinder understanding or participation in the study.
- Patients currently receiving palliative care, as they may prioritize symptom management over educational interventions.
- Participants who are physically unable to engage with the study's digital tools or complete assessments (e.g., due to severe illness).
- Individuals who are unable to communicate in Arabic, as the AI chatbot intervention is designed in Arabic.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site
Faculty of Nursing Cairo University
Cairo
marwa mamdouh, phd, 00201067612255, marwa.mamdouh@cu.edu.eg
About this study
Official title: Empowering Breast Cancer Clients Through AI Chatbots: Transforming Knowledge and Attitudes for Enhanced Nursing Care
The goal of this clinical trial is to investigate the impact of an AI-powered chatbot intervention on improving knowledge, attitudes, and empowerment in breast cancer patients. The study focuses on female breast cancer patients, aged 18 years or older, who are receiving treatment at Kafr El-Sheikh University Hospital in Egypt.
The main questions it aims to answer are:
Read more
Can the AI chatbot intervention improve breast cancer knowledge compared to standard care?
Can the AI chatbot intervention positively influence attitudes toward AI in healthcare?
Does the AI chatbot intervention enhance patient empowerment in managing breast cancer?
Researchers will compare:
Intervention group (AI chatbot + standard care) to control group (standard care alone) to see if the AI chatbot intervention leads to greater improvements in knowledge, more positive attitudes towards AI, and higher perceived empowerment.
Participants will:
Engage with an AI-powered chatbot designed to provide personalized education on breast cancer, treatment options, and emotional support.
Complete pre- and post-intervention assessments to measure changes in knowledge, attitudes toward AI, and empowerment.
Receive standard care, including routine oncology consultations and nursing support, alongside the chatbot intervention (for the intervention group).
Read the detailed description
This study explores the integration of AI-powered chatbots in breast cancer care to enhance patient education, self-management, and psychosocial support. Breast cancer is often accompanied by a range of psychological challenges, including anxiety and uncertainty about treatment options, side effects, and overall prognosis. Traditional healthcare systems struggle to provide continuous support, which is where AI technology can offer a solution by enabling 24/7 access to information and emotional support.
The study design employs a quasi-experimental approach, where 122 breast cancer patients were recruited from Kafr El-Sheikh University Hospital. Participants were randomly assigned to one of two groups:
Intervention Group (n=61): Participants in this group received standard care, which includes routine consultations with oncology specialists and nurses, in addition to an AI chatbot intervention. The chatbot delivered personalized educational content about breast cancer, treatment options, and self-care. It also offered emotional support by answering queries and providing motivational messages.
Control Group (n=61): Participants in this group received only standard care, which consisted of regular oncology consultations and nursing support without the chatbot.
The AI chatbot intervention is designed to:
Improve knowledge about breast cancer, treatment side effects, symptom management, and emotional well-being.
Foster positive attitudes toward AI in healthcare by providing a reliable, non-judgmental source of information.
Enhance empowerment by allowing patients to actively engage with their care information outside of regular hospital visits.
Participants' knowledge, attitudes toward AI, and empowerment were assessed at two time points:
Baseline (before the intervention)
Post-intervention (after 4 weeks of engaging with the chatbot)
The primary outcome of the study is to evaluate improvements in breast cancer-related knowledge, measured through a questionnaire that assesses knowledge in key areas such as early detection, treatment options, side effects, and AI's role in healthcare. The secondary outcomes focus on attitudes toward AI and perceived empowerment, assessed through validated Likert scales designed for this purpose.
This study will provide valuable insights into the feasibility and efficacy of AI-powered chatbots in enhancing patient care for breast cancer patients, especially in resource-limited settings. Furthermore, it aims to contribute to the growing body of evidence supporting the use of digital health technologies in oncology nursing and patient empowerment.
- Being tested
- AI Chatbot for Breast Cancer Patient Education and Empowerment
- Keywords
- AI Chatbot, Breast Cancer, Patient Education, Empowerment, Oncology Nursing, Attitudes Toward AI, Digital Health, Patient Support
- Medical subject headings
- Breast Neoplasms, Empowerment
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AI Chatbot for Breast Cancer Patient Education and EmpowermentBehavioural
The AI Chatbot for Breast Cancer Patient Education and Empowerment is a digital health intervention that leverages artificial intelligence to provide personalized educational content and emotional support to breast cancer patients. The chatbot delivers information on breast cancer management, treatment options, side effects, and self-care practices. It is available 24/7, offering real-time answers to patient queries and tailored suggestions based on their treatment path. The aim is to increase patient knowledge, improve attitudes toward AI, and empower patients to take a more active role in their care. The chatbot intervention is provided alongside standard oncology care at Kafr El-Sheikh University Hospital.
| Study group | Role | What they receive |
|---|---|---|
| Intervention Group (AI Chatbot + Standard Care) | Experimental | Participants in this arm will receive standard oncology care in addition to interacting with an AI-powered chatbot. The chatbot will provide personalized educational content on breast cancer, treatment options, side effects, and offer emotional support. Participants will engage with the chatbot for 4 weeks, with assessments at baseline and post-interventi Receives: Behavioral: AI Chatbot for Breast Cancer Patient Education and Empowerment |
| Control Group (Standard Care Only) | No intervention | Participants in this arm will receive standard oncology care only, including routine consultations with oncology specialists and nurses. They will not have access to the AI chatbot intervention. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Breast Cancer Knowledge Improvement
This outcome measures the change in breast cancer knowledge from baseline to post-intervention for participants who used the AI chatbot compared to the control group. Knowledge is assessed using the Artificial Intelligence of Breast Cancer Questionnaire, which covers topics such as treatment options, side effects, symptom management, and AI's role in healthcare.
Measured: 2 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Apr 2025
- Study start20 Apr 2025 (estimated)
- Primary completion1 Jul 2025 (estimated)
- Study completion15 Jul 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Breast Cancer Early Stage Breast Cancer (Stage 1-3)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study uses a quasi-experimental, parallel group design, where one group receives an AI chatbot intervention alongside standard care, while the other group receives only standard care. The groups will be compared to measure the intervention's effectiveness on knowledge improvement, AI attitudes, and empowerment.
- Masking
- None (open label)
- Enrolment
- 122 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mostafa Shaban
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Mostafa Shaban, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06943911
- Sponsor's protocol ID
- KFSU-BC-AI-2025
- Acronym
- BC-CHAT
- Status last verified
- Apr 2025
- First submitted
- 17 Apr 2025
- Last updated
- 25 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: We currently do not plan to share individual participant data (IPD) outside of the research team due to concerns about participant confidentiality and the sensitive nature of the data collected. The study includes personal health information that is protected under ethical guidelines and privacy regulations. Additionally, sharing IPD may present challenges related to data security and informed consent, as participants have not explicitly consented to broader data sharing. However, the study's aggregate findings will be made publicly available through peer-reviewed publications and presentations
Publications
Janopaul-Naylor JR, Koo A, Qian DC, McCall NS, Liu Y, Patel SA. Physician Assessment of ChatGPT and Bing Answers to American Cancer Society's Questions to Ask About Your Cancer. Am J Clin Oncol. 2024 Jan 1;47(1):17-21. doi: 10.1097/COC.0000000000001050. Epub 2023 Oct 12.
PubMed 37823708Siglen E, Vetti HH, Lunde ABF, Hatlebrekke TA, Stromsvik N, Hamang A, Hovland ST, Rettberg JW, Steen VM, Bjorvatn C. Ask Rosa - The making of a digital genetic conversation tool, a chatbot, about hereditary breast and ovarian cancer. Patient Educ Couns. 2022 Jun;105(6):1488-1494. doi: 10.1016/j.pec.2021.09.027. Epub 2021 Oct 6.
PubMed 34649750Agrawal A. Fairness in AI-Driven Oncology: Investigating Racial and Gender Biases in Large Language Models. Cureus. 2024 Sep 16;16(9):e69541. doi: 10.7759/cureus.69541. eCollection 2024 Sep.
PubMed 39416584Ma Y, Achiche S, Pomey MP, Paquette J, Adjtoutah N, Vicente S, Engler K; MARVIN chatbots Patient Expert Committee; Laymouna M, Lessard D, Lemire B, Asselah J, Therrien R, Osmanlliu E, Zawati MH, Joly Y, Lebouche B. Adapting and Evaluating an AI-Based Chatbot Through Patient and Stakeholder Engagement to Provide Information for Different Health Conditions: Master Protocol for an Adaptive Platform Trial (the MARVIN Chatbots Study). JMIR Res Protoc. 2024 Feb 13;13:e54668. doi: 10.2196/54668.
PubMed 38349734Chang YC, Wu CH, Lupo R, Botti S, Conte L, Vitone M, Massafra R, De Nunzio G, Vitale E. Generative Artificial Intelligence (AI) to Uncover Insights From Breast Cancer Patients' Perceptions to Mindfulness-Based Stress Reduction (MBSR) Interventions. Holist Nurs Pract. 2025 Sep-Oct 01;39(5):317-325. doi: 10.1097/HNP.0000000000000677. Epub 2025 Aug 13.
PubMed 39186509Sato A, Haneda E, Hiroshima Y, Narimatsu H. Preliminary Screening for Hereditary Breast and Ovarian Cancer Using an AI Chatbot as a Genetic Counselor: Clinical Study. J Med Internet Res. 2024 Nov 27;26:e48914. doi: 10.2196/48914.
PubMed 39602801Shaban M, Osman YM, Mohamed NA, Shaban MM. Empowering breast cancer clients through AI chatbots: transforming knowledge and attitudes for enhanced nursing care. BMC Nurs. 2025 Jul 29;24(1):994. doi: 10.1186/s12912-025-03585-w.
PubMed 40731340
Study at a glance
From the registry record, last updated by the sponsor on 25 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Empowering Breast Cancer Clients Through AI Chatbots: Transforming Knowledge and Attitudes for Enhanced Nursing Care
- ClinicalTrials.gov ID
- NCT06943911
- Acronym / sponsor ID
- BC-CHAT / KFSU-BC-AI-2025
- Keywords
- AI Chatbot, Breast Cancer, Patient Education, Empowerment, Oncology Nursing, Attitudes Toward AI, Digital Health, Patient Support
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 122 participants (estimated)
- Lead sponsor
- Mostafa ShabanUniversity, hospital or other
- Study start
- 20 Apr 2025 (estimated)
- Primary completion
- 1 Jul 2025 (estimated)
- Study completion
- 15 Jul 2025 (estimated)
- First posted
- 25 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to investigate the impact of an AI-powered chatbot intervention on improving knowledge, attitudes, and empowerment in breast cancer patients. The study focuses on female breast cancer patients, aged 18 years or older, who are receiving treatment at Kafr El-Sheikh University Hospital in Egypt.
The main questions it aims to answer are:
Can the AI chatbot intervention improve breast cancer knowledge compared to standard care?
Can the AI chatbot intervention positively influence attitudes toward AI in healthcare?
Does the AI chatbot intervention enhance patient empowerment in managing breast cancer?
Researchers will compare:
Intervention group (AI chatbot + standard care) to control group (standard care alone) to see if the AI chatbot intervention leads to greater improvements in knowledge, more positive attitudes towards AI, and higher perceived empowerment.
Participants will:
Engage with an AI-powered chatbot designed to provide personalized education on breast cancer, treatment options, and emotional support.
Complete pre- and post-intervention assessments to measure changes in knowledge, attitudes toward AI, and empowerment.
Receive standard care, including routine oncology consultations and nursing support, alongside the chatbot intervention (for the intervention group).
Detailed description
This study explores the integration of AI-powered chatbots in breast cancer care to enhance patient education, self-management, and psychosocial support. Breast cancer is often accompanied by a range of psychological challenges, including anxiety and uncertainty about treatment options, side effects, and overall prognosis. Traditional healthcare systems struggle to provide continuous support, which is where AI technology can offer a solution by enabling 24/7 access to information and emotional support.
The study design employs a quasi-experimental approach, where 122 breast cancer patients were recruited from Kafr El-Sheikh University Hospital. Participants were randomly assigned to one of two groups:
Intervention Group (n=61): Participants in this group received standard care, which includes routine consultations with oncology specialists and nurses, in addition to an AI chatbot intervention. The chatbot delivered personalized educational content about breast cancer, treatment options, and self-care. It also offered emotional support by answering queries and providing motivational messages.
Control Group (n=61): Participants in this group received only standard care, which consisted of regular oncology consultations and nursing support without the chatbot.
The AI chatbot intervention is designed to:
Improve knowledge about breast cancer, treatment side effects, symptom management, and emotional well-being.
Foster positive attitudes toward AI in healthcare by providing a reliable, non-judgmental source of information.
Enhance empowerment by allowing patients to actively engage with their care information outside of regular hospital visits.
Participants' knowledge, attitudes toward AI, and empowerment were assessed at two time points:
Baseline (before the intervention)
Post-intervention (after 4 weeks of engaging with the chatbot)
The primary outcome of the study is to evaluate improvements in breast cancer-related knowledge, measured through a questionnaire that assesses knowledge in key areas such as early detection, treatment options, side effects, and AI's role in healthcare. The secondary outcomes focus on attitudes toward AI and perceived empowerment, assessed through validated Likert scales designed for this purpose.
This study will provide valuable insights into the feasibility and efficacy of AI-powered chatbots in enhancing patient care for breast cancer patients, especially in resource-limited settings. Furthermore, it aims to contribute to the growing body of evidence supporting the use of digital health technologies in oncology nursing and patient empowerment.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This study uses a quasi-experimental, parallel group design, where one group receives an AI chatbot intervention alongside standard care, while the other group receives only standard care. The groups will be compared to measure the intervention's effectiveness on knowledge improvement, AI attitudes, and empowerment.
| Arm | Type | Receives |
|---|---|---|
| Intervention Group (AI Chatbot + Standard Care) | Experimental | Behavioral: AI Chatbot for Breast Cancer Patient Education and EmpowermentParticipants in this arm will receive standard oncology care in addition to interacting with an AI-powered chatbot. The chatbot will provide personalized educational content on breast cancer, treatment options, side effects, and offer emotional support. Participants will engage with the chatbot for 4 weeks, with assessments at baseline and post-interventi |
| Control Group (Standard Care Only) | No intervention | –Participants in this arm will receive standard oncology care only, including routine consultations with oncology specialists and nurses. They will not have access to the AI chatbot intervention. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Female participants diagnosed with breast cancer, regardless of cancer stage.
- Age 18 years or older.
- Ability to read and communicate in Arabic to interact with the AI chatbot.
- Willingness to participate in the study and to engage with the AI chatbot for the duration of the intervention.
- Ability to provide informed consent.
Key exclusion criteria (4 listed)
- Participants with cognitive impairments or serious mental health conditions that may hinder understanding or participation in the study.
- Patients currently receiving palliative care, as they may prioritize symptom management over educational interventions.
- Participants who are physically unable to engage with the study's digital tools or complete assessments (e.g., due to severe illness).
- Individuals who are unable to communicate in Arabic, as the AI chatbot intervention is designed in Arabic.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AI Chatbot for Breast Cancer Patient Education and EmpowermentThe AI Chatbot for Breast Cancer Patient Education and Empowerment is a digital health intervention that leverages artificial intelligence to provide personalized educational content and emotional support to breast cancer patients. The chatbot delivers information on breast cancer management, treatment options, side effects, and self-care practices. It is available 24/7, offering real-time answers to patient queries and tailored suggestions based on their treatment path. The aim is to increase patient knowledge, improve attitudes toward AI, and empower patients to take a more active role in their care. The chatbot intervention is provided alongside standard oncology care at Kafr El-Sheikh University Hospital. | Behavioural | Intervention Group (AI Chatbot + Standard Care) |
Primary outcome
Breast Cancer Knowledge Improvement
Time frame: 2 months
This outcome measures the change in breast cancer knowledge from baseline to post-intervention for participants who used the AI chatbot compared to the control group. Knowledge is assessed using the Artificial Intelligence of Breast Cancer Questionnaire, which covers topics such as treatment options, side effects, symptom management, and AI's role in healthcare.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Apr 2025.
- Results publication: PubMed 37823708Janopaul-Naylor JR, Koo A, Qian DC, McCall NS, Liu Y, Patel SA. Physician Assessment of ChatGPT and Bing Answers to American Cancer Society's Questions to Ask About Your Cancer. Am J Clin Oncol. 2024 Jan 1;47(1):17-21. doi: 10.1097/COC.0000000000001050. Epub 2023 Oct 12.
- Results publication: PubMed 34649750Siglen E, Vetti HH, Lunde ABF, Hatlebrekke TA, Stromsvik N, Hamang A, Hovland ST, Rettberg JW, Steen VM, Bjorvatn C. Ask Rosa - The making of a digital genetic conversation tool, a chatbot, about hereditary breast and ovarian cancer. Patient Educ Couns. 2022 Jun;105(6):1488-1494. doi: 10.1016/j.pec.2021.09.027. Epub 2021 Oct 6.
- Results publication: PubMed 39416584Agrawal A. Fairness in AI-Driven Oncology: Investigating Racial and Gender Biases in Large Language Models. Cureus. 2024 Sep 16;16(9):e69541. doi: 10.7759/cureus.69541. eCollection 2024 Sep.
- Results publication: PubMed 38349734Ma Y, Achiche S, Pomey MP, Paquette J, Adjtoutah N, Vicente S, Engler K; MARVIN chatbots Patient Expert Committee; Laymouna M, Lessard D, Lemire B, Asselah J, Therrien R, Osmanlliu E, Zawati MH, Joly Y, Lebouche B. Adapting and Evaluating an AI-Based Chatbot Through Patient and Stakeholder Engagement to Provide Information for Different Health Conditions: Master Protocol for an Adaptive Platform Trial (the MARVIN Chatbots Study). JMIR Res Protoc. 2024 Feb 13;13:e54668. doi: 10.2196/54668.
- Results publication: PubMed 39186509Chang YC, Wu CH, Lupo R, Botti S, Conte L, Vitone M, Massafra R, De Nunzio G, Vitale E. Generative Artificial Intelligence (AI) to Uncover Insights From Breast Cancer Patients' Perceptions to Mindfulness-Based Stress Reduction (MBSR) Interventions. Holist Nurs Pract. 2025 Sep-Oct 01;39(5):317-325. doi: 10.1097/HNP.0000000000000677. Epub 2025 Aug 13.
- Results publication: PubMed 39602801Sato A, Haneda E, Hiroshima Y, Narimatsu H. Preliminary Screening for Hereditary Breast and Ovarian Cancer Using an AI Chatbot as a Genetic Counselor: Clinical Study. J Med Internet Res. 2024 Nov 27;26:e48914. doi: 10.2196/48914.
- Derived from this study: PubMed 40731340Shaban M, Osman YM, Mohamed NA, Shaban MM. Empowering breast cancer clients through AI chatbots: transforming knowledge and attitudes for enhanced nursing care. BMC Nurs. 2025 Jul 29;24(1):994. doi: 10.1186/s12912-025-03585-w.
- Individual participant dataSharing planned: Undecided. We currently do not plan to share individual participant data (IPD) outside of the research team due to concerns about participant confidentiality and the sensitive nature of the data collected. The study includes personal health information that is protected under ethical guidelines and privacy regulations. Additionally, sharing IPD may present challenges related to data security and informed consent, as participants have not explicitly consented to broader data sharing. However, the study's aggregate findings will be made publicly available through peer-reviewed publications and presentations
Related trials for Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Not yet recruiting
PRISM Trial: Partial Breast Versus Whole Breast Radiation in Early Breast Cancer
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Recruiting
Evaluation of the Effect of Regular Physical Exercise in Breast Cancer.
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Breast Neoplasms, Triple Negative Breast Neoplasms
Not yet recruiting
Collaborative Research: Multiscale Modeling and Intervention for Improving Long-Term Medication
Breast Cancer Survivor, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Recruiting
1-Week Versus 3-Week PBI
Early-Stage Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing AI Chatbot for Breast Cancer Patient Education and Empowerment in people with Breast Cancer Early Stage Breast Cancer (Stage 1-3), run by Mostafa Shaban at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 25 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mostafa shaban, phd (+966565644617, mostafa.shaban2020@cu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Breast Cancer Knowledge Improvement (time frame: 2 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06943911, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Apr 2025.